Bulk Pharmaceutical API Sources for EMADINE

Bulk Pharmaceutical API Sources for EMADINE

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		3219
ABI Chem		AC1L1FFW
ChemMol		49422421

EMADINE Bulk Active Pharmaceutical Ingredient (API) Sourcing

Last updated: February 19, 2026

This analysis identifies current and potential bulk active pharmaceutical ingredient (API) sources for EMADINE, a therapeutic agent. It details key manufacturers, their production capacities, regulatory compliance, and notable market positioning.

What is EMADINE?

EMADINE is a brand name for the prescription antihistamine emedastine difumarate [1]. It is used to treat the itchy eyes associated with allergic conjunctivitis [2]. Emedastine difumarate is a selective H1 receptor antagonist.

Global EMADINE API Manufacturers

Several manufacturers supply bulk EMADINE API. These companies operate under various regulatory frameworks and possess distinct production capabilities.

• Wuhan Huaya Pharmaceutical Co., Ltd.: Based in China, Wuhan Huaya Pharmaceutical is a significant supplier of pharmaceutical intermediates and APIs. The company states its adherence to Good Manufacturing Practices (GMP) [3]. Specific production volumes for EMADINE are not publicly disclosed but the company lists it among its catalog of available APIs.

• Capot Chemical Co., Ltd.: Another Chinese-based chemical supplier, Capot Chemical provides a range of research chemicals and APIs. They list EMADINE difumarate in their product offerings, indicating an ability to synthesize the compound [4]. Their facilities are subject to Chinese regulatory oversight.

• Santa Cruz Biotechnology, Inc.: This U.S.-based biotechnology company offers a broad spectrum of biochemicals, including APIs for research and development purposes. They list emedastine difumarate in their catalog [5]. Their role is primarily in the distribution of research-grade materials, not large-scale GMP manufacturing for commercial drug products.

• Toronto Research Chemicals (TRC): TRC, a part of LGC Standards, specializes in the synthesis of complex organic chemicals, including APIs and their metabolites, for research. They supply emedastine difumarate [6]. TRC's focus is on high-purity compounds for R&D, often in smaller quantities than required for commercial API production.

• Key API Manufacturing Regions: China is a dominant region for bulk API production due to established manufacturing infrastructure and cost efficiencies. India is also a major global supplier of APIs, though specific EMADINE manufacturers in India are not prominently featured in public sourcing databases for this particular compound. European and North American manufacturers often focus on more complex or niche APIs, or the final drug product formulation.

Regulatory Compliance and Quality Standards

The sourcing of bulk EMADINE API requires stringent adherence to quality and regulatory standards to ensure patient safety and drug efficacy.

• Good Manufacturing Practices (GMP): Manufacturers supplying API for pharmaceutical products intended for regulated markets (e.g., United States, European Union) must comply with GMP guidelines. These guidelines cover all aspects of production, from raw material sourcing to finished product testing and documentation. Manufacturers like Wuhan Huaya Pharmaceutical state their compliance with GMP [3].

• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). A DMF provides confidential, detailed information about the manufacturing process, facilities, and quality control of the API. It allows drug product manufacturers to reference the API information without full disclosure to their competitors [7]. The availability of a DMF can significantly streamline the drug product approval process. Specific DMF status for EMADINE API from the listed suppliers is not readily available in public databases.

• Certifications and Audits: Manufacturers may hold certifications from various international bodies or undergo audits by their pharmaceutical clients. These demonstrate a commitment to quality management systems.

• Geographic Considerations: API sourced from China is subject to the regulations of China's National Medical Products Administration (NMPA) and often undergoes inspections by foreign regulatory bodies if intended for export. Similarly, APIs from India are regulated by the Central Drugs Standard Control Organization (CDSCO).

Market Dynamics and Sourcing Considerations

Sourcing bulk EMADINE API involves evaluating market dynamics, supplier reliability, and cost-effectiveness.

• Supplier Landscape: The market for EMADINE API is characterized by a mix of specialized chemical synthesis companies and broader API manufacturers. The primary production base appears to be in China, catering to global demand.

• Pricing: API pricing is influenced by manufacturing complexity, scale of production, raw material costs, and regulatory compliance expenses. Manufacturers in lower-cost regions often offer competitive pricing. Specific price points for EMADINE API are subject to direct negotiation and depend on order volume and purity specifications.

• Lead Times and Supply Chain Reliability: Factors such as production schedules, raw material availability, and logistics impact lead times for API delivery. Establishing reliable supply chains involves due diligence on supplier capacity, historical performance, and risk mitigation strategies.

• Purity and Specifications: EMADINE API must meet predefined purity standards and physical specifications to be suitable for pharmaceutical formulation. This includes the absence of significant impurities and adherence to parameters like particle size distribution and polymorphic form, which can affect drug product stability and bioavailability.

• Research vs. Commercial Grade: It is crucial to distinguish between suppliers offering research-grade chemicals (e.g., Santa Cruz Biotechnology, Toronto Research Chemicals) and those capable of producing commercial-grade, GMP-compliant API. Research-grade materials are unsuitable for use in approved drug products.

EMADINE API Manufacturing Capacity and Scale

Estimating precise manufacturing capacity for specific APIs like EMADINE is challenging as this data is proprietary. However, general trends in bulk chemical synthesis provide an indication.

• Batch Production: Bulk API is typically produced in batches. The size of these batches can range from tens of kilograms to several metric tons, depending on the demand for the API and the manufacturer's reactor capacity.

• Dedicated vs. Multi-purpose Facilities: Larger API manufacturers may have dedicated production lines for high-volume products. Smaller or more specialized companies utilize multi-purpose facilities capable of producing a variety of compounds.

• Scalability: A key consideration for pharmaceutical companies is the ability of an API supplier to scale production up or down based on market demand for the final drug product.

• Market Volume: The global market volume for EMADINE API is directly tied to the prescription volume of EMADINE-containing eye drops. While precise figures are not publicly available, the market is likely moderate, served by a limited number of core manufacturers.

Potential Risks and Mitigation Strategies in Sourcing

Sourcing APIs, including EMADINE, carries inherent risks that require proactive mitigation.

• Quality Failures: Batch-to-batch variability or outright quality failures can lead to production delays and regulatory issues. Mitigation involves rigorous supplier qualification, including audits, and comprehensive incoming material testing.

• Supply Chain Disruptions: Geopolitical events, natural disasters, or unexpected plant shutdowns can disrupt supply. Diversifying the supplier base across different geographic regions can help mitigate this risk.

• Intellectual Property (IP) and Regulatory Changes: Changes in patent landscapes or evolving regulatory requirements can impact the sourcing and use of APIs. Staying informed about regulatory updates is critical.

• Counterfeit or Substandard APIs: The risk of encountering counterfeit or substandard APIs exists, particularly from less reputable sources. Thorough due diligence on suppliers and their certifications is essential.

• Cost Volatility: Raw material price fluctuations and changes in manufacturing costs can impact API pricing. Long-term supply agreements with price adjustment clauses can offer some stability.

Key Takeaways

• Bulk EMADINE API is primarily sourced from manufacturers based in China, with Wuhan Huaya Pharmaceutical and Capot Chemical identified as suppliers.
• Regulatory compliance, particularly adherence to GMP standards and the potential availability of DMFs, is critical for sourcing API intended for commercial drug products.
• Differentiating between research-grade and commercial-grade API suppliers is essential, with Santa Cruz Biotechnology and Toronto Research Chemicals offering materials for R&D purposes.
• Sourcing considerations include supplier reliability, quality control, lead times, and cost-effectiveness, with diversification of the supplier base recommended to mitigate supply chain risks.

Frequently Asked Questions

1. What is the typical lead time for ordering bulk EMADINE API from Chinese manufacturers? Lead times can vary significantly but typically range from 8 to 16 weeks, depending on current production schedules, raw material availability, and shipping logistics.

2. Does EMADINE API require a specific polymorphic form for formulation? Yes, the specific polymorphic form of an API can impact its stability, solubility, and bioavailability. Pharmaceutical companies will have defined specifications for the polymorphic form of EMADINE API required for their drug product.

3. Are there any specific FDA or EMA guidelines for EMADINE API manufacturing that differ from general API requirements? While EMADINE itself is not subject to unique manufacturing guidelines beyond general API requirements, its use in an ophthalmic product means that stringent controls on particle size, sterility (if applicable to API handling), and absence of endotoxins are crucial aspects of quality control.

4. What are the main impurities to monitor in EMADINE API production? Key impurities to monitor include related substances from the synthesis pathway, residual solvents, and potential degradation products. Detailed impurity profiles are typically provided in the manufacturer's Certificate of Analysis (CoA) and can be further elaborated in their DMF.

5. How can a company verify the GMP compliance of a new EMADINE API supplier? Verification typically involves reviewing the supplier's GMP certification, requesting audit reports (or conducting a direct audit), examining their quality management system documentation, and potentially performing qualification batches of the API.

Citations

[1] Emedastine. (n.d.). PubChem. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Emedastine

[2] EMADINE (emedastine difumarate) ophthalmic solution. (n.d.). RxList. Retrieved from https://www.rxlist.com/emadine-drug.htm

[3] Wuhan Huaya Pharmaceutical Co., Ltd. (n.d.). API List. Retrieved from https://www.huayapharm.com/api-list/

[4] Capot Chemical Co., Ltd. (n.d.). EMADINE difumarate. Retrieved from https://www.capotchem.com/product/EMADINE-difumarate-101825-75-8.html

[5] Santa Cruz Biotechnology, Inc. (n.d.). Emedastine difumarate. Retrieved from https://www.scbt.com/p/emedastine-difumarate-101825-75-8

[6] Toronto Research Chemicals. (n.d.). Emedastine difumarate. Retrieved from https://www.trc-le.com/product/emedastine-difumarate-101825-75-8

[7] U.S. Food and Drug Administration. (2021, May 7). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-file-dmfs/drug-master-files-dmfs